Vaccine for Atherosclerosis  by Shah, Prediman K. et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 4 , N O . 2 5 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 0 . 0 1 8THE PRESENT AND FUTURE
STATE-OF-THE-ART REVIEWVaccine for Atherosclerosis
Prediman K. Shah, MD,* Kuang-Yuh Chyu, MD, PHD,* Paul C. Dimayuga, PHD,* Jan Nilsson, MD, PHDyABSTRACTFro
Me
Ma
va
pa
Dr
Lis
Yo
MaAtherosclerosis is an immune-mediated inﬂammatory disease of the arterial wall, with both the innate and adaptive
immune systems responding to many endogenous and exogenous antigens. Both proatherogenic as well as atheropro-
tective roles have been identiﬁed for the immune system in atherosclerosis. Hence, it is conceivable that an immuno-
modulatory strategy via active immunization against many of these antigens could potentially alter the natural history of
atherosclerosis. This review discusses: 1) the complex role of important components of the innate and adaptive immune
systems in atherogenesis; 2) the nature of many antigens that have been tested successfully in vaccine formulations to
reduce atherosclerosis in pre-clinical experimental models; and 3) the potential opportunities and challenges for clinical
application of vaccination for atherosclerosis in the future. (J Am Coll Cardiol 2014;64:2779–91) © 2014 by the American
College of Cardiology Foundation.S ubstantial data from experimental and clinicalinvestigation support the role of immune-mediated inﬂammatory mechanisms in athero-
genesis. Cells of both the innate and adaptive immune
systems, such as macrophages, dendritic cells (DCs),
B and T lymphocytes, and mast cells, are ubiquitous
in atherosclerotic plaques (1,2). Immunoinﬂammatory
mediators such as pathogen- and danger-associated
molecular pattern molecules, immunoglobulins, cyto-
kines, chemokines, and complement proteins are all
present to varying degrees in the atherosclerotic pla-
que (3,4). In atherosclerosis-prone areas of the murine
aorta, especially in the adventitia, antigen-presenting
cells are already present in greater numbers than in
atheroresistant segments, even before hyperlipidemia
or atherosclerotic lesions are introduced, suggesting
that there is immunoinﬂammatory priming in these
segments (5).
INNATE IMMUNITY AND ATHEROSCLEROSIS. Innate
immunity reﬂects a nonspeciﬁc immediate response to
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sentinels and ﬁrst responders, sampling the host
environment to detect molecular signatures of damage
or danger, such as oxidatively-modiﬁed low-density
lipoprotein (oxLDL). These molecular signatures of
damage or danger, which are perceived by the host as
molecular insults to the vascular wall, interact with
toll-like receptors. Toll-like receptors act as pattern-
recognition receptors, leading to the activation of
genes involved in acute inﬂammation and the eventual
release of inﬂammatory cytokines that characterize the
acute innate immune response. Disruption of genes
involved in this innate immune signaling pathway
reduces atherosclerosis, plaque inﬂammation, and
circulating inﬂammatory proteins in mice, indepen-
dent of changes in circulating cholesterol levels (6).
Proatherogenic roles for innate immune cells are
demonstrated by the deletion of genes involved in
their differentiation and proliferation. Hypercho-
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DC = dendritic cell
HSP = heat shock protein
Ig = immunoglobulin
LDL = low-density lipoprotein
LDLR = low-density
lipoprotein receptor
MHC = major
histocompatibility class
NK = natural killer
oxLDL = oxidatively-modiﬁed
low-density lipoprotein
Treg = regulatory T
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2780for macrophage survival and proliferation,
have markedly reduced atherosclerosis
despite severe hypercholesterolemia (7).
Accumulating evidence also suggests di-
versity in the subtypes of mononuclear cells
involved in innate immune responses. Studies
in mice identiﬁed 2 subtypes of monocytes, 1
of which is considered proinﬂammatory,
bearing high Ly6C expression as a marker (8).
This inﬂammatory subset of high Ly6C
monocytes was proposed to be precursors of
proinﬂammatory M1 macrophages found in
the plaques. Another phenotypic subset of
macrophages is M2 macrophages, which, in a
simpliﬁed phenotypic classiﬁcation, are in-volved in resolution of plaque (9,10). Although this
simpliﬁed view of monocyte-macrophages helps
investigators to better understand the phenotypic
heterogeneity ofmonocyte-macrophages in vitro, real,
in vivo phenotypic changes are likely much more
complex and not quite so discrete (9–11).
Natural killer (NK) cells are another innate
immune cell type that contributes to atherosclerotic
lesion formation. Low-density lipoprotein receptor-
deﬁcient (LDLR/) mice repopulated with bone
marrow cells from Ly49A transgenic mice deﬁcient in
functional NK cells developed smaller atherosclerotic
lesions in the aortic root and arch compared with
LDLR/ mice receiving bone marrow cells from non-
transgenic donors (12). Depletion of NK cells in apoli-
poprotein (apo) E/ mice using anti-asialo-GM1
antibodies reduced atherosclerosis. Adoptive transfer
of wild-type NK cells into apoE/Rag-2/ interleukin
2rg/ mice augmented lesion size, conﬁrming the
proatherogenic role of NK cells. The proatherogenic
function of NK cells appears to be dependent on
mediators such as perforin and granzyme B (13).
Mast cells also accumulate in atherosclerotic
lesions, and hypercholesterolemic mice lacking mast
cells have reduced inﬂammation and lesion formation
(14–16). Interestingly, 2 of these studies reported
lower circulating cholesterol levels in mast cell–
deﬁcient mice, suggesting a link between innate mast
cell signaling and cholesterol homeostasis (15,16).
DCs bridge the innate immune system with the
adaptive immune response and are the upstream
component in the chain of immune cell activation.
This unique position makes DCs an important target
when considering potential strategies to modulate
atherosclerosis. Resident intimal DCs rapidly ingest
lipid in hypercholesterolemic conditions, whereas
depleting DCs using CD11c-speciﬁc diphtheria toxin
receptor (DTR) transgenic mice resulted in re-
duced early lesion formation in LDLR/ mice (17),supporting a proatherogenic role for conventional
DCs. This study conﬁrmed a previous report using
genetic deletion of CD11c in apoE/mice (18). Murine
and human atherosclerotic lesions contain plasmacy-
toid dendritic cells (pDCs). Exposure to oxLDL enables
pDCs to elicit antigen-speciﬁc T cell responses.
Depleting pDCs using antimouse plasmacytoid den-
dritic cell antigen-1 antibody in apoE/mice reduced
atherosclerosis in the aortic sinus and was associated
with reduced plaque inﬂammation and global sup-
pression of T cell activation (19). The atherosclerosis-
enhancing role of pDCs was mediated by activation of
immune responses by autoantigens through protein-
deoxyribonucleic acid (DNA) complexes (20).
ADAPTIVE IMMUNITY AND ATHEROSCLEROSIS.
Compared with the blunt, nonspeciﬁc nature of the
innate immune system, the adaptive immune
response is more speciﬁc and develops over time
through stochastic rearrangement during immuno-
blast development, generating a wide variety of T
and B cell receptors that recognize speciﬁc antigens.
Innate immune cells, such as DCs and macrophages,
present antigens in the context of the major histo-
compatibility complex for recognition by T cells. T
cell activation occurs upon presentation of the anti-
gen in the setting of an inﬂammatory state, resulting
in clonal proliferation. CD8þ T cell clonal proliferation
involves increased cytokine production and cytotoxic
function targeted against cells presenting the speciﬁc
antigen. CD4þ T cell activation also results in cyto-
kine production, which, in turn, skews subsequent B
cell activation to produce speciﬁc immunoglobulins.
Prior work with B cells suggested a protective role
against atherosclerosis in hypercholesterolemic mice
(21). A series of elegant studies by the Witztum group
showed that natural antibodies of the immunoglob-
ulin (Ig) M isotype are reactive with the phosphor-
ylcholine head group present in oxidized low-density
lipoprotein (LDL), apoptotic cells, and the cell wall of
Pneumococcus. These natural antibodies of the IgM
isotype attenuated atherosclerosis (22–24), support-
ing the role of molecular mimicry in atherogenesis.
These IgM antibodies are produced by self-renewing
B1 cells, lending support to the protective role of B
cells in atherogenesis (25). In contrast to these
studies, B cell depletion using anti-CD20 antibody
reduced atherosclerosis (26), suggesting that a more
intricate balance of B cell subtypes is likely involved.
Studies targeting the B cell activating factor pathway
in murine atherosclerosis support this concept
(27,28). B cell activating factor deletion resulted in
reduced B2 cells with a preserved B1 cell population,
and was associated with reduced atherosclerosis.
Thus, cumulative evidence suggests that there is cell
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2781subtype speciﬁcity in the role of B cells in atheroscle-
rosis, with B1 cells having an atheroprotective effect,
whereas B2 cells have a proatherogenic effect.
Recently, the effect of passive immunomodulation
using single- or multiple-dose infusion of a mono-
clonal anti-oxLDL antibody (MLDL1278A, aka BI-204)
was tested in a small phase 2 multicenter, random-
ized, double-blind, placebo-controlled trial involving
stable atherosclerotic cardiovascular disease patients
(NCT01258907). The 12-week study was designed to
measure the effect of the antibody on carotid and aortic
vascular inﬂammation, as determined by 18F
2-deoxyglucose positron emission tomography imag-
ing. The study failed to meet its primary endpoint of
reduction in vascular inﬂammation, as measured
by target to background ratio for vascular 18F
2-deoxyglucose uptake with the antibody treatment
(29). The full and ﬁnal results of this trial have not yet
been published. The precise reasons for this trial’s
negative results remain unclear, but may include the
failure to enrich the population with subjects more
likely to have lipid-rich and highly-inﬂamed plaques,
who would have been the most likely to respond to
treatment. Uncertainty about the accuracy of the im-
aging technique used in the trial may also have
contributed to the negative results. Nevertheless,
these negative ﬁndings do not have any direct impli-
cations for active vaccination strategy, especially
when the strategy works by altering cell-mediated
immune responses.
Human atherosclerotic plaques contain macro-
phages and DCs, both of which can function as
antigen-presenting cells (APCs), as well as T cells that
express markers of activation (30). Evidence of APC–T
cell interaction suggests antigen-speciﬁc immune
activation through immunologic synapses in the
plaque (31). CD4þ T cells were initially reported to
have a generalized proatherogenic role. This was
supported by HLA-DR–restricted oxLDL activation of
CD4þ T cells cloned from atherosclerotic plaques (32).
Adoptive transfer of CD4þ T cells into immunodeﬁ-
cient hypercholesterolemic mice aggravated athero-
sclerosis (33). The proatherogenic role of CD4þ T cells
is, in part, due to the exaggerated proinﬂammatory
effect of the Th1 cytokine response, particularly
interferon-g (34,35). Increased atherosclerosis after
adoptive transfer of CD4þ T cells reactive to LDL
supported the postulated role of LDL as an antigen
source for CD4þ T cell responses in atherosclerosis
(36). Other reports suggested that certain Th2 cyto-
kine responses, such as IL-10, are protective against
atherosclerosis (37,38). However, not all Th2 cytokine
responses are atheroprotective. Deﬁciency of IL-4,
another prototypical Th2 cytokine, in bone marrow–derived cells achieved by a bone marrow transplant
strategy in LDLR/ mice resulted in reduced
atherosclerosis in speciﬁc sites of the vascular tree,
suggesting a proatherogenic role of IL-4 (39). ApoE/
mice genetically deﬁcient in IL-4 also developed
reduced atherosclerosis formation when compared
with apoE/ mice, further supporting a proathero-
genic role of IL-4 (40). In addition to CD4þ Th2 cells,
other types of immune cells, such as mast cells,
macrophages, and NK cells, secrete Th2 cytokines.
The heterogeneous involvement of these many
different types of cells, and their possible interaction
with Th1 response, makes a uniﬁed interpretation of
the role of Th2 response in atherogenesis difﬁcult, as
outlined in a recent excellent review (41).
Another subtype of CD4þ T cells that has gained
attention in the ﬁeld of atherosclerosis research is
CD4þ regulatory T (Treg) cells (42,43). The conven-
tional immunology paradigm divides CD4þ Treg cells
into natural or adaptive Treg cells. Natural Treg cells
develop in the thymus with high CD25 expression and
speciﬁcity against self-antigens, whereas adaptive
Treg cells develop from mature T-cell populations
under antigenic stimulation with variable levels of
CD25 expression and speciﬁcity against tissue and
foreign antigens (44). However, CD25 is not exclu-
sively a marker for Treg cells. A more reliable Treg cell
marker is expression of the transcription factor,
FoxP3, which distinguishes CD4þCD25þ Treg cells
from their CD4þCD25þ T effector cell counterparts.
Depletion of CD4þCD25þ Treg cells by deletion of
CD80/CD86, CD28 or with CD25 neutralizing antibody
resulted in increased atherosclerosis (42,45). Selec-
tive deletion of FoxP3þ cells using either a diphtheria
toxin receptor transgenic approach (46) or by vacci-
nation against FoxP3 (47) resulted in increased
atherosclerosis in hypercholesterolemic mice. Thus,
experimental evidence from pre-clinical studies
supports the notion that CD4þ Treg cells have athe-
roprotective properties. Clinical studies also showed
that the number of CD4þCD25þ Treg cells in peripheral
blood from patients with acute coronary syndrome
was reduced and their ability to suppress responder
CD4þ T cell proliferation was compromised compared
with cells from patients with stable angina and sub-
jects with normal coronary arteries (48,49). Similar
reductions of FoxP3 expression in peripheral
CD4þCD25þ Treg cells and decreased frequency of
CD4þCD25þFoxP3þ T cells in patients with aortic
aneurysm have also been reported (50). Another
prospective study revealed that low levels of base-
line CD4þFoxP3þ T cells were associated with an
increased risk of developing acute coronary syn-
drome 11 to 14 years later, suggesting that patients
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2782with low baseline levels of CD4þFoxP3þ T cells
have the propensity to develop a higher burden of
atherosclerotic coronary disease (51).
Investigators are keenly interested in the natural
killer subtype of T cells (NKT), due to their ability to
recognize lipid antigens presented in a CD1-restricted
manner. CD1 molecules are present in atherosclerotic
plaques and colocalize in areas of the arterial walls
containing T cells, indicating potential interaction
between CD1þ cells and T cells (52). Genetic deletion
of CD1d in hypercholesterolemic mice reduced lesion
size (53,54), and activation of NKT cells using a
synthetic glycolipid, a-galactosylceramide, increased
atherosclerosis (53–55). However, not all NKT cells
are atherogenic. ApoE/ mice rendered NKT cell-
deﬁcient by day-3 neonatal thymectomy developed
smaller atherosclerotic lesions. Adoptive transfer of
CD4þ, not double negative NKT cells, into thymec-
tomized apoE/ mice promoted atherosclerotic
lesion formation. These data suggest differential roles
of NKT cell subtypes in atherogenesis (56).
CD8þ T cells were initially sidelined, partly due to
the lack of observed effects on atherogenesis in mice
with gene deletions that severely reduced or elimi-
nated CD8þ T cells (57,58). However, subsequent
studies reported that CD8þ T cell activation occurred
earlier than CD4þ T cell response in the setting ofand Complex Interactions Among Components of Innate and
in Atherogenesis
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milieu was reported to enhance T cell activation and
function in both CD4þ and CD8þ cell subtypes (60). A
study that used depleting antibodies in hypercholes-
terolemic mice showed a pathogenic role for CD8þ T
cells in atherosclerosis, supporting the role of CD8þ T
cells in atherogenesis (61). In a recent prospective
clinical study, a higher fraction of CD8þ T cells
correlated with characteristics of insulin resistance
such as a high waist–hip ratio and high fasting plasma
glucose, insulin, and triglyceride levels. Patients with
the 2 highest tertiles of CD8þ T cells displayed a trend
toward increased incidence of coronary events during
follow-up for 11 to 14 years (62). Additional work with
CD8þ T cells in atherogenesis showed complexity in
the subtypes involved. CD8þCD25þ T cells adoptively
transferred into hypercholesterolemic mice reduced
atherosclerosis associated with immunomodulatory
functions (63). Thus, similar to CD4þ T cells, regula-
tory subtypes of CD8þ T cells may also function to
down-regulate immune responses in atherosclerotic
diseases. This function of CD8þ T cells is in line with
the historic reference to this cell type as suppressor
T cells. Further investigations are still needed for a
more clear understanding of the role of CD8þ T cell
subtypes in atherogenesis.
As summarized in the preceding text, numerous
components of the innate and adaptive immune
systems participate in modulating atherogenesis,
with intricate interactions among these components
that can lead to either worsening or amelioration of
atherosclerosis (Figure 1). Given a major role for
the adaptive immune system in atherosclerosis, its
modulation with vaccination provides an opportunity
for a potential atherosclerosis treatment strategy.
Several candidate antigens for vaccination are under
investigation, with LDL and its protein component,
apoB-100, at the forefront.
CONCEPT OF A VACCINE FOR
ATHEROSCLEROSIS
RATIONALE FOR A VACCINATION STRATEGY. Given
that immune-mediated inﬂammation is a cardinal
feature of atherosclerosis, it is tempting to consider
speciﬁc strategies to target immune or inﬂammatory
components as a novel approach against inﬂamma-
tion and atherosclerosis. The pathophysiologic role of
inﬂammation in atherosclerosis is currently being
tested in human trials using anti-inﬂammatory drugs
(64,65). These approaches are predicated on the
notion that dampening the inﬂammatory response
may favorably affect the clinical outcome by reducing
atherothrombotic cardiovascular events.
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2783Modulation of the athero-promoting adaptive im-
mune response is another potentially attractive
strategy against atherosclerosis. Immune activation
during atherogenesis is an inevitable host response;
thus, ﬁne-tuning this response may prove beneﬁcial
in atherosclerosis. The challenge of this approach is to
identify speciﬁc antigens relevant to atherogenesis so
that they can be used to activate an antigen-speciﬁc
atheroprotective immune response. Most studies in
search of potential antigens are in pre-clinical
experimental stages; hence, unless otherwise stated,
data discussed in the subsequent sections of this re-
view come from animal models of atherosclerosis.
EXOGENOUS SOURCES OF REACTIVE ANTIGENS. A
reasonable approach to searching for antigens would
be to focus on the disease itself: the atherosclerotic
plaque. Many foreign antigens, including bacteria
such as Mycoplasma pneumoniae, Chlamydia pneu-
moniae, and Porphyromonas gingivalis and viruses
such as hepatitis C virus, enteroviruses, human
immunodeﬁciency virus, and cytomegalovirus, have
been identiﬁed in atherosclerotic plaques (66). It is
unclear if these pathogens are causative agents,
directly participating in the pathogenesis of athero-
sclerosis, or if they provide conditions that skew the
immune response to more inﬂammatory activity
through molecular mimicry, rendering arterial walls
more prone to atherosclerosis formation. Many clin-
ical trials using antibiotics to treat Chlamydia infec-
tion failed to prevent cardiovascular events (67–74).
Because the results can be viewed either as evidence
not in support of such a role or as suggesting that
failure resulted from initiating antibiotic treatment
too late to have signiﬁcant clinical impact, they do
not resolve the issue of whether pathogens play a
causative role in atherogenesis.TABLE 1 Summary of the Studies of Active Immunization Using LDL o
Animal (Ref. #) Antigens Immu
LDLR/ rabbits (132) MDA-LDL Subcutaneo
NZW rabbits on high
cholesterol diet (133)
Native LDL or
Cuox-LDL
Subcutaneo
LDLR/ mice (134) Native LDL or
MDA-LDL
Subcutaneo
ApoE/ mice (135) MDA-LDL Subcutaneo
ApoE/ mice (136) Plaque homogenate
or MDA-LDL
Foot pad in
ApoE/ mice (137) Native LDL Subcutaneo
ApoE/ or apoE/CD4 double
knockout mice (138)
MDA-LDL Subcutaneo
LDLR/ mice (120) Cuox-LDL Intravenous
oxLDL-p
ApoE/ mice (139) Cuox-LDL Nasal delive
Apo ¼ apolipoprotein; Cuox ¼ copper-oxidized; LDL ¼ low-density lipoprotein; LDLR ¼ lo
oxLDL ¼ oxidatively-modiﬁed low-density lipoprotein.Periodontal pathogens have recently gained
attention in the research community, as many are
found in human atherosclerotic lesions (66) and have
been linked to atherosclerosis (75–78). Exposure of
experimental animals to P. gingivalis accelerates
atherosclerosis formation (79–81), whereas immuni-
zation against P. gingivalis attenuates such pathogen-
induced atherosclerosis (82). At this time, a direct role
for these pathogens in human atherosclerosis remains
uncertain, thus it is unclear whether vaccines tar-
geting periodontal pathogens would be a useful
strategy in human subjects.
ENDOGENOUS ANTIGENS. Search for LDL and
apoB-100–der ived ant igens . Because LDL and
other apoB-100–containing lipoproteins are the pri-
mary culprits with the strongest causative link with
atherothrombosis, antigens derived from them
remain prime candidates for vaccine development.
Immunization of experimental animals with homol-
ogous whole native or oxidatively-modiﬁed LDL
incorporated into a vaccine formulation with dif-
ferent adjuvants has clearly and consistently
demonstrated atheroprotective effects; however, the
precise mechanisms and antigenic epitopes are not
fully deﬁned (Table 1).
Because LDL is a large, heterogeneous molecule
containing a diverse cargo of apolipoproteins, cho-
lesteryl esters, triglycerides, and phospholipids, it
would be impractical to use whole homologous LDL
as an antigen in a clinically-usable vaccine formula-
tion. Its complexity makes it difﬁcult to determine
the exact immunogenic epitopes within the LDL
molecule. Safety issues during isolation of large
quantities of LDL for vaccine formulation are an-
other concern. Given the promising experimental
data from immunization using LDL as antigen, itr its Modiﬁed Form as Antigens to Modulate Atherosclerosis
nization Route Effect on Atherosclerosis
us Reduced (aorta)
us Reduced (aorta)
us Reduced (aortic sinus)
us Reduced (aortic sinus)
jection Reduced (aortic sinus)
us Reduced (aortic sinus)
us Reduced (aortic sinus)
delivery of
ulsed dendritic cells
Reduced (accelerated carotid atherosclerosis
induced by pericarotid collar)
ry Reduced (aortic sinus and aorta)
w-density lipoprotein receptor; MDA ¼malondialdehyde; NZW ¼ New Zealand white;
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tective antigenic epitopes in LDL. To do this, we
initiated an extensive effort to identify potential
antigenic epitopes within apoB-100, the major pro-
tein component of LDL and other atherogenic lipo-
proteins, which could then be used as antigens to
achieve atheroprotective effects via immunization.
We initially screened the entire 4,536-amino acid
human apoB-100 protein and designed a library of
302 peptides (each 20 amino acids long with a
5-amino acid overlap with the preceding sequence)
spanning the entire apoB-100 sequence. Out of these
20-mer peptide sequences, 102 peptides to which an
immune response with antibodies was detected in
pooled human plasma were identiﬁed (83). Subse-
quent testing revealed that several immunoreactive
peptides, including p2, p143, and p210, resulted in
a 40% to 70% decrease in atherosclerosis and reduc-
tion in plaque inﬂammation when used in a vaccine
formulation in hypercholesterolemic mice (84,85).
Our research teams in the United States and Sweden
have been using p210 as a prototype antigen in vac-
cine formulations because the p210-based vaccine
has delivered the most consistent atheroprotective
effects (86–88). Because knowledge of the deﬁned
epitope makes more deﬁnitive immunologic studies
possible, this move away from using the whole LDL
particle as an antigen and toward using more deﬁned
apoB-100 peptides as antigens is a crucial step in
development of pre-clinical prototypes of an athero-
sclerosis vaccine.
Mechan isms of act ion of p210 vacc ine . Immuni-
zation with the p210 vaccine resulted in a signiﬁcant
reduction of aortic atherosclerosis compared with
control subjects (88). Given that immunization acti-
vates both B and T cells (88), it is important to
delineate the subset(s) of lymphocytes that mediate
the p210 vaccine’s atheroprotective effect. At this
time, no strong experimental evidence supports a role
for the humoral response in the protective effect of
active immunization using the p210 vaccine. The
atheroprotective effects of apoB-100 peptide immu-
nization occurred without an increase in peptide-
speciﬁc IgG, as reported with LDLR/ human
apoB-100 transgenic mice (86), and the induced
antibody titers did not correlate with the lesion
size (87). Adoptive transfer of B cells from p210-
immunized mice to nonimmunized recipient mice
did not confer the atheroprotective effect (88).
However, in the course of the immunization study,
we observed changes in p210 antibody levels in
apoE/ mice. Both p210 IgM and IgG titers were low
before immunization, with p210 IgM titers increasing
over time, regardless of whether or not mice wereimmunized with p210 vaccine. IgG titers against p210
followed a different trend: in control mice, there was
no signiﬁcant change of IgG titer between baseline
and 25 weeks, whereas mice receiving adjuvant only
or p210 vaccine developed high p210 IgG titer at 25
weeks. Interestingly, the IgG titer at 25 weeks from
p210-immunized mice was signiﬁcantly lower than
that of mice receiving adjuvant only. This observation
suggests that: 1) there is an endogenous IgM immune
response against p210, with adjuvant recipients or
p210 vaccine recipients inducing antibody class
switching to IgG; and 2) induction of p210 IgG could
potentially serve as a marker of vaccination effect,
even though it does not correlate with the athero-
protective efﬁcacy of the p210 vaccine.
In addition to reducing aortic atherosclerosis, p210
vaccine also activated CD8þ T cells, along with a
reduction of dendritic cells at the site of immuniza-
tion and within the atherosclerotic plaques. These
observations led us to postulate that CD8þ T cells
could be the immune cells that mediate the vaccine’s
atheroprotective effect. Subsequent experiments
involving adoptive transfer of CD8þ T cells from p210
immunized mice into naïve, nonimmunized mice
indeed recapitulated the atheroprotective effect
of active immunization and, thus, conﬁrmed our
postulate. Modulation of dendritic cells by p210 vac-
cine appeared to be antigen-speciﬁc, because effector
CD8þ T cells from p210-immunized mice developed a
preferentially higher cytolytic response against p210-
loaded dendritic cells in vitro. This may explain the
reduction in dendritic cells seen in the immunization
sites and atherosclerotic plaques. The observed
modulation of DCs and cellular immune responses
did not alter the efﬁcacy of subsequent T cell–
dependent or independent immune response to other
irrelevant antigens (88).
In addition to the CD8þ T cell response, p210
immunization also elicited a CD4þ T cell response.
The reduction of atherosclerosis by p210 immuni-
zation was associated with a CD4þCD25þ T cell
response. Administration of antibodies against CD25
reduced CD4þCD25þ T cells and abrogated the athe-
roprotective effect of p210 immunization (89). In
addition, Dr. Klingenberg’s group (87) immunized
female apoE/ mice intranasally twice weekly for 12
weeks with a recombinant protein consisting of p210
fused with the cholera toxin B subunit (CTB). Control
mice received ovalbumin peptide fused with CTB or
PBS as control. Mucosal immunization using p210-
CTB reduced atherosclerosis in aortic sinuses of
mice. The investigators also observed that splenic
CD4þ T cells from p210-CTB–immunized mice con-
tained a higher percentage of the IL-10þ subset, which
FIGURE 2 CD8þ T Cells Elicited by p210 Immunization Modulate
Spontaneous Atherosclerosis
Spontaneous atherosclerosis
LDL
apoB-100
Immature DCs Presentation of
apoB-100 peptide
Epitopes by DCs
DC-T cell
interaction via TCR
Antigen-specific
cytolysis against
DCs by CD8+ T cells
CD8+ T cellsImmature DCs Modulation of
CD8+ T cell function
Generation of CD4+ Treg cells
Atherosclerosis
p210 immunization
p210
Processing and presentation of endogenous LDL and its ApoB-100 peptide epitopes by DCs
induce atherogenic antigen-speciﬁc T cell responses leading to atherosclerosis. Immuni-
zation with p210 generates cytolytic CD8þ T cells that lyse antigen-presenting DCs, and
hence down-regulate atherogenic immune response to LDL and its apoB-100 peptides.
Dotted line depicts lack of direct evidence to show how CD4þ Treg cells induced by p210
immunization reduce atherosclerosis. Abbreviations as in Figure 1.
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CD4þ T cells, without any differences between p210-
CTB and control subjects in FoxP3, IL-10, or TGF-b
messenger ribonucleic acid expression in the
aorta (87). Furthermore, there was no difference in
the numbers of FoxP3þ cells in aortic lesions or
CD4þFoxP3þ T cells in lung mucosa (87). Further
evidence of the atheroprotective effects of p210 was
provided by Herbin et al. (90), who implanted a mini-
osmotic pump to subcutaneously deliver a mixture of
apoB-100 peptides (p210, malondialdehyde-modiﬁed
[MDA]-p210 and p240) or p210 alone for 2 weeks.
Such treatment reduced atherosclerotic lesions in
aortic sinuses 10 weeks later compared with control
subjects and also retarded the progression of estab-
lished atherosclerotic lesions in old female mice (90).
Subcutaneous peptide delivery was associated with
reduced activation of CD4þ T cells and an increased
CD4þCD25þFoxP3þ subset of T cells in lymph nodes.
Ablation of CD25þ T cells by CD25-depleting antibody
abrogated the atheroprotective effects of subcutane-
ous infusion of apoB-100 peptides, similar to the
study by Wigren et al. (89). On the basis of these
reports, there is clearly a CD4þ T cell response (be it
induction of CD4þCD25þ or CD4þIL-10þ T cells) with
p210 immunization. However, there is no direct evi-
dence suggesting that these CD4þ T cell responses
mediate the atheroprotective effect of p210 immuni-
zation, nor what the target cell types of these CD4þ
T cells are.
These different cellular immune responses elicited
by p210 in various reports could be due to the dif-
ference in: 1) the form of p210 delivered—carrier
conjugated, recombinant with CTB, or free form;
2) route of delivery—subcutaneous versus mucosal;
3) doses of p210; or 4) duration of p210 delivery—
long-term depot effect of carrier-conjugated p210 in
subcutaneous tissue versus infusion for 2 weeks.
Nevertheless, the consistent reduction of atheroscle-
rosis after p210 immunization, regardless of how and
which form was delivered, strongly suggests that
p210 is a promising candidate antigen for potential
vaccine formulation for possible future human
application. Our experimental studies suggest that
there is an endogenous immune response to p210 in
hypercholesterolemic challenge and that p210 vacci-
nation modulates the functions of certain subsets of
CD8þ T cells that regulate the endogenous p210 im-
mune response in a feedback-dependent fashion
(Figure 2).
Other apoB-100– re la ted ant igens . A peptide with
apoB-100 amino-acid residues 688 to 707 has been
incorporated into a multiantigenic construct with
peptidic epitopes from Chlamydophila pneumoniaeand heat shock protein (HSP) 60. Immunization with
such multiple antigenic epitopes reduced athero-
sclerosis accompanied by a reduction of macrophage
inﬁltration and an increase of CD4þFoxP3 T cells in
the plaques (91).
Using a different approach to identify possible
apoB-100 epitopes in a major histocompatibility class
(MHC)-II restricted context, Dr. Klaus Ley’s group (92)
recently surveyed the murine apoB-100 protein for
peptide fragments that were predicted by modeling
algorithms to bind to the mouse MHC-II molecule
I-Ab. The survey predicted 2 peptide fragments,
ApoB3501-3516 and ApoB978-993, which also reduced
atherosclerosis when used to immunize apoE/
mice, possibly via an IL-10–dependent mechanism
(92). Recently, Dr. Hansson’s group (93) generated
T cell hybridomas from human apoB-100 transgenic
mice immunized with human oxLDL and identiﬁed
ApoB-100–responding CD4þ T cell hybridomas.
These hybridomas were MHC class II–restricted and
expressed a single T cell receptor V beta chain,
TRBV31. Use of a TRBV31-derived peptide in a vaccine
formulation induced anti-TRBV31 antibodies that
blocked T cell recognition of apoB-100 and sig-
niﬁcantly reduced atherosclerosis (93). Thus, the
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fying a potentially pathogenic CD4þ T cell population
and used antigen-speciﬁc humoral immunity, deter-
mined by the speciﬁc signature of these CD4þ T cells
to block a proatherogenic cellular immune response,
and hence conﬁrming the pathogenic role of CD4þ
T cells in atherosclerosis.
OTHER ANTIGENS IN VACCINE DEVELOPMENT FOR
ATHEROSCLEROSIS. The approach of using vaccines
to modulate immune responses in atherosclerosis has
not been limited to LDL and apoB-100–related
antigens. The complexity of atherosclerotic vascular
disease presents the opportunity to target other
potential sources of antigens.
Other l ip id- re lated ant igens . A natural IgM anti-
body recognizing the epitopes in oxLDL (94,95) and
phosphorylcholine (PC) headgroups on the surface of
apoptotic cells, and which inhibits uptake of oxLDL
and apoptotic cells by macrophages, has been exten-
sively studied (22,94,96). Protection against infection
from Streptococcus pneumoniae is attributed to
anti-PC antibodies (97,98). Active immunization with
S. pneumoniae in LDLR/ mice to induce anti-PC
antibodies resulted in increased oxLDL antibodies,
primarily of the IgM isotype, and reduced athero-
sclerosis (23). The increase in oxLDL-speciﬁc IgM is
attributed to the cross-reactivity of the phosphor-
ylcholine moiety on oxLDL with S. pneumoniae-
induced antibodies, suggesting molecular mimicry
between S. pneumoniae and oxLDL. This molecular
mimicry was investigated and expanded further in
the context of a vaccine by Caligiuri et al. (99) using
phosphorylcholine (PC), the reported mimotope. The
group used the PC-keyhole limpet hemocyanin-
conjugate coupled to CpG oligonucleotides as adju-
vant and immunized apoE/ mice with multiple
interperitoneal injections. The PC immune serum
signiﬁcantly increased IgG and IgM antibodies against
PC and oxLDL, with reduced macrophage oxLDL
uptake, and reduced atherosclerosis (99). However,
observational cohort studies in humans, using
myocardial infarction or stroke as endpoints, did not
show consistent protective effects of pneumococcal
vaccines (100–103). Whether active immunization
against PC will result in reduced atherosclerosis still
awaits validation.
In rabbits, active immunization with cholesteryl
ester transfer protein (CETP), a key enzyme involved
in high-density lipoprotein (HDL) metabolism,
induced neutralizing antibodies and markedly
increased HDL-C levels concomitant with reduced
atherosclerosis (104–106). However, a phase 1 human
trial did not show consistent induction of CETPantibody or signiﬁcant changes in CETP function or
HDL levels with CETP immunization (107).
Vacc ines target ing HSP ant igens . HSPs are stress
proteins that are highly conserved in all organisms.
They are present in cells under normal conditions and
can be expressed at high levels when cells are
exposed to stresses, such as altered pH or oxygen
deprivation. HSPs have also been implicated in
atherogenesis (108–111). However, the effect of im-
munization with HSPs on atherosclerosis has been
inconsistent. Several groups reported that immuni-
zation with HSP65 induces atherosclerotic lesions
(112–114), whereas others reported reduced athero-
sclerotic lesions (115,116). The difference in outcomes
highlights the likely effect of the adjuvant used, as
well as the mode of antigen delivery. Prior studies
reporting increased atherosclerosis with HSP65 used
Freund’s adjuvant, which induces a strong inﬂam-
matory response. However, Klingenberg et al. (115)
used alum as the adjuvant, with the authors propos-
ing that, given its nature as a microbial constituent,
HSP65 itself may act as both antigen and adjuvant,
with alum acting as a modulating factor. The immune
response constituted an increase in B cell activity,
most noticeably in HSP65 IgG1, with a similar trend
in oxLDL IgG and reduced atherosclerosis (115).
In addition to the subcutaneous route, vaccines
may also be delivered through nasal mucosa,
and mucosal immunity appears to elicit a down-
modulation of immune responses to speciﬁc anti-
gens. In a recent report, the vaccines used either
DNA, whole protein HSP65, or both in PBS with
multiple intranasal vaccinations in rabbits. All
vaccine formulations induced HSP65 IgG responses,
increased serum interleukin (IL)-10, and reduced
interferon-g, and reduced atherosclerosis accompa-
nied by decreased cholesterol levels (116).
Vacc ines aga inst host ce l l sur face and extra-
ce l lu la r matr ix prote ins . The involvement of
certain inﬂammatory cells in atherosclerotic plaque
formation suggested that speciﬁc cell surface markers
could be potential antigens for immunization. Stra-
tegies targeting cell surface proteins thought to
contribute to atherosclerosis have been tested using
DNA vaccines. DNA vaccines formulated for oral
administration have been used experimentally with
success. Also called transgenic vaccination, the anti-
gen is delivered via an expression plasmid that
encodes the antigen. Oral immunization is thought to
work through transfer of the genetic material from
the carrier to host phagocytes in the gastrointestinal
tract. The phagocytes then express the antigen
de novo in the cytosol, and present it on MHC
molecules (117). In studies using this approach in
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CD99 (118) or vascular endothelial growth factor
receptor-2 (119) carried by live attenuated Salmonella
typhimurium and delivered orally. In these studies,
the expressed antigens were presented in the context
of MHC-I, which elicited a CD8þ cytolytic T cell
response targeting cells that expressed vascular
endothelial growth factor receptor 2 or CD99, result-
ing in reduced atherosclerosis.
LDL retention in the arterial wall by extracellular
matrix (ECM) is an early step in the development of
atherosclerotic lesions. Fibronectin is an ECM protein
found in plaques. Immunization with ﬁbronectin
formulated with alum as the adjuvant signiﬁcantly
reduced atherosclerosis in apoE/ mice, and was
associated with increased Th2-type antibody pro-
duction and increased regulatory T cells (120). Inter-
estingly, plasma cholesterol was signiﬁcantly reduced
in the immunized mice, suggesting that there is an
interaction between immune responses to ECM pro-
teins and cholesterol metabolism.
Dendr i t i c ce l l vacc ines . Because DCs are the most
efﬁcient antigen-presenting cells, antigen delivery by
DCs into the host should provoke an efﬁcient
response. This is achieved by transferring autologous
or syngeneic DCs loaded with the speciﬁc antigen to
naïve recipients. Several groups tested this in pre-
clinical studies using different antigen formulations.
Habets et al. (121) used oxLDL as the antigen with
lipopolysaccharide (LPS) as the maturation factor,
and transferred the cells into naïve recipient mice
intravenously 3 times. Transfer of oxLDL-loaded DCs
induced a Th1 response, increased oxLDL IgG titers,
and reduced atherosclerosis (121).
Using apoB-100 as the antigen, Hermansson et al. (122)
again treated DCs with LPS but added IL-10 to induce a
tolerogenic phenotype. Using only a single intravenous
transfer strategy, atherosclerosis inmicewas signiﬁcantly
reduced. This was accompanied by increased CD4þIL-10þ
T cells, increased FoxP3 messenger ribonucleic acid
expression in the spleen, and reduced lymphocyte pro-
liferation after apoB-100 stimulation, suggesting an
immunoregulatory function. In anothermouse study, the
same investigators loaded DCs with MDA-modiﬁed LDL,
alsowith LPS as amaturation factor, butwithout cytokine
treatment, and injected the loaded DCs subcutaneously
multiple times over several weeks (123). This resulted in
increased atherosclerosis with increased MDA-LDL IgG
response and MDA-LDL–stimulated T cell proliferation.
Because the group had previously shown reduced
atherosclerosis with MDA-LDL immunization formulated
with CFA, they performed a short study to determine
immune responses with the 2 vaccination approaches.
They found that MDA-LDL emulsiﬁed in CFA-inducedCD4þCD25þFoxP3þ T regulatory cells, whereas MDA-
LDL loaded DCs did not, suggesting that vaccine formu-
lation and delivery signiﬁcantly affects the outcome.
Inﬂuenza vaccination and cardiovascular events.
Documents from professional societies advocate
inﬂuenza vaccination to patients with cardiovascular
disease for secondary prevention of further cardio-
vascular events (124). Studies have shown increased
rates of acute myocardial infarction and death during
the inﬂuenza season, suggesting that there is an as-
sociation between cardiovascular events and inﬂu-
enza infection (125). Although its causal role in
triggering cardiovascular events remains to be eluci-
dated, experimental studies have shown that the
inﬂuenza virus promotes arterial and plaque inﬂam-
mation (126,127). Three small, randomized clinical
trials conducted outside of the United States
demonstrated consistent reductions in cardiovascular
events (such as rehospitalization for ischemia), but
less consistency in reduction of cardiovascular death
(128–130). A recent meta-analysis further suggested a
beneﬁt of inﬂuenza vaccine for secondary protection
of cardiovascular events (131). These reports provide
evidence to support further studies on the use of the
inﬂuenza vaccine to reduce rates of acute myocardial
infarctions and to understand its mechanism of
action, which is not yet known. It is possible that
vaccination results in reduced inﬂammatory signaling
in atherosclerotic plaques, leading to reduced acute
cardiovascular events, a mechanism different from
those for the antigens described in the preceding
sections.
IMPLICATIONS AND CLINICAL PERSPECTIVES
Vaccines and clean water are the 2 major public
health advances of the past 100 years. Vaccines have
had a major impact in virtually eradicating many
infectious diseases; therefore, the idea of developing
vaccination strategies for the chronic, highly preva-
lent disease of atherosclerosis, which takes a consid-
erable toll on human lives across the globe, is both
exciting and daunting. In this review, we discussed
the experimental evidence for induction of antigen-
speciﬁc immune responses relevant in athero-
sclerosis by vaccination (Central Illustration). The
adaptive immune system is a powerful tool, used by
the host to attempt homeostasis when challenged.
Successful harnessing of this powerful tool will be
an important contribution to the host arsenal for
combatting atherosclerotic disease. However, there
are clear challenges for clinical translation.
Translation of the aforementioned promising pre-
clinical observations into the clinical arena is in its
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2788infancy. Many questions remain to be answered while
designing proper clinical studies. These include (but
are not limited to) questions regarding: vaccine safety
and stability; schedule and durability of immuniza-
tion; proper selection of patient populations for
testing; and determination and monitoring of efﬁcacy
endpoints in clinical studies. In addition, how an
approach would potentially impact current patient
managementwith strategies such as lipid lowering and
lifestyle changes must be considered. With all of these
challenges in mind, we are cautiously optimistic about
the potential for future clinical application. Currently,
as discussed in this review, we have many choices of
antigens that can be tested for human application.
Firm evidence from numerous clinical trials hasestablished the causative role of LDL in atherogenesis,
which makes LDL and apoB-100 reasonable and
logical initial targets for immunomodulatory therapy.
Pre-clinical studies using LDL or apoB-100 peptides as
candidate antigens in vaccine formulation further
support such a claim. It is time to muster together the
academic investigators, professional societies, gov-
ernment agencies, funding organizations, and phar-
maceutical industries needed to initiate this long-term
journey into clinical application.
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